Regarding the significant involvement of both main targets for biological treatment in RA - TNFα and IL-6 - in hematopoiesis regulation, our results emphasize the importance of the monitoring of the patient ́s complete hematological profile during biological therapy. This evidence concerns the gene IL6 and rheumatoid arthritis.